Blood mononuclear cell nitric oxide production and plasma cytokine levels in healthy gabonese children with prior mild or severe malaria

Infection and Immunity

Volumn 67, Issue 9, 1999, Pages 4977-4981

  Perkins, Douglas J ^a,b   Kremsner, Peter G ^b,c   Schmid, Daniela ^b,c   Misukonis, Mary A ^a   Kelly, Meghan A ^a   Weinberg, J Brice ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Research Unit   (Gambia)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYTOKINE PRODUCTION; DISEASE MARKER; ENZYME ACTIVITY; GABON; HOST RESISTANCE; HUMAN; HUMAN EXPERIMENT; INFECTION RESISTANCE; MALARIA; NORMAL HUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL;

EID: 0032788610     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.9.4977-4981.1999     Document Type: Article

References (33)

1. Anstey, N., D. Granger, and J. Weinberg. 1999. Nitric oxide in malaria, p. 311-341. In F. Fang (ed.), Nitric oxide and infection. Plenum Press, New York, N.Y.
2. Anstey, N. M., J. B. Weinberg, M. Hassanali, E. D. Mwaikambo, D. Manyenga, M. A. Misukonis, D. R. Antelle, D. Hollis, M. I. McDonald, and D. L. Granger. 1996. Nitric oxide in Tanzanian children with malaria. Inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J. Exp. Med. 184:557-567.
3. Fahmi, H., D. Charon, M. Mondange, and R. Chaby. 1995. Endotoxininduced desensitization of mouse macrophages is mediated in part by nitric oxide production. Infect. Immun. 63:1863-1869.
4. Florquin, S., Z. Amraoui, C. Dubois, J. Decuyper, and M. Goldman. 1994. The protective role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice. J. Exp. Med. 180:1153-1158.
5. G-monomethyl-L-argirune. J. Immunol. 146:1294-1302.
6. Granger, D. L., W. C. Miller, and J. B. Hibbs, Jr. 1996. Methods of analyzing nitric oxide production in the immune response, p. 603-617. In M. Feelisch and J. S. Stamler (ed.), Methods in nitric oxide research. John Wiley & Sons Ltd., New York, N.Y.
7. Grau, G. E., T. E. Taylor, M. E. Molyneux, J. J. Wirima, P. Vassalli, M. Hommel, and P. H. Lambert 1989. Tumor necrosis factor and disease severity in children with falciparum malaria. N. Engl. J. Med. 320:1586-1591.
8. Gyan, B., M. Troye-Blomberg, P. Perlmann, and A. Bjorkman. 1994. Human monocytes cultured with and without interferon-gamma inhibit Plasmodium falciparum parasite growth in vitro via secretion of reactive nitrogen intermediates. Parasite Immunol. 16:371-375.
9. Iuvone, T., F. Dacquisto, R. Carnuccio, and M. Dirosa. 1996. Nitric oxide inhibits LPS-induced tumor necrosis factor synthesis in vitro and in vivo. Life Sci. 59:PL207-PL211.
10. Kern, P., C. J. Hemmer, J. Van Dame, H. J. Gruss, and M. Dietrich. 1989. Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated malaria. Am. J. Med. 87:139-143.
11. Kremsner, P., S. Neifer, M. Chaves, R. Rudolph, and U. Bienzle. 1992. Interferon-γ induced lethality in the late phase of Plasmodium vinckei malaria despite effective parasite clearance by chloroquine. Eur. J. Immunol. 22:2873-2878.
12. Kremsner, P. G., S. Winkler, E. Wildling, J. Prada, U. Bienzle, W. Graninger, and A. K. Nussler. 1996. High plasma levels of nitrogen oxides are associated with severe disease and correlate with rapid parasitological and clinical cure in Plasmodium falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 90:44-47.
13. Kun, J., R. Schmidt-Ott, L. Lehman, B. Lell, D. Luckner, B. Greve, P. Matousek, and P. Kremsner. 1998. Merozoite surface antigen 1 and 2 genotypes and resetting of Plasmodium falciparum in severe and mild malaria in Lambarene, Gabon. Trans. R. Soc. Trop. Med. Hyg. 92:110-114.
14. Kun, J. F. J., B. Mordmuller, B. Lell, L. G. Lehman, D. Luckner, and P. G. Kremsner. 1998. Polymorphism in promoter region of inducible nitric oxide synthase gene and proteclion against malaria. Lancet 351:265-266.
15. Kwiatkowski, D., A. V. Hill, I. Sambou, P. Twumasi, J. Castracane, K. R. Manogue, A. Cerami, D. R. Brewster, and B. M. Greenwood. 1990. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falcipanun malaria. Lancet 336:1201-1204.
16. Kwiatkowski, D., M. Molyneux, S. Stephens, N. Curtis, N. Klein, P. Pointaire, M. Smit, R Allan, D. Brewster, G. Grau, et al. 1993. Anti-TNF therapy inhibits fever in cerebral malaria. Q. J. Med. 86:91-98.
17. McGuire, W., A. V. Hill, C. E. Allsopp, B. M. Greenwood, and D. Kwiatkowski. 1994. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 371:508-510.
18. McGuire, W., J. Knight, A. Hill, C. Allsopp, B. Greenwood, and D. Kwiatkowski. 1999. Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J. Infect. Dis. 179:287-290.
19. Mellouk, S., S. L. Hoffman, Z.-Z. Liu, P. de la Vega, T. R. Billiar, and A. K. Nussler. 1994. Nitric oxide-mediated antiplasmodial activity in human and murine hepatocytes induced by gamma Interferon and the parasite itself: enhancement by exogenous tetrahydrobiopterin. Infect. Immun. 62:4043-4046.
20. Nussler, A., J.-C. Drapier, L. Renia, S. Pied, F. Miltgen, M. Gentilini, and D. Mazier. 1991. L-Arginine-dependent destruction of intrahepatic malaria parasites in response to tumor necrosis factor and/or interleukin-6 stimulation. Eur. J. Immunol. 21:227-230.
21. Oswald, I. P, T. A. Wynn, A. Sher, and S. L. James. 1994. NO as an effector molecule of parasite killing: modulation of its synthesis by cytokines. Comp. Biochem. Physiol. Pharmacol. Toxicol. Endocrinol. 108:11-18.
22. Rockett, K. A., M. M. Awburn, W. B. Cowden, and I. A. Clark. 1991. Killing of Plasmodium falciparum in vitro by nitric oxide derivatives. Infect. Immun. 59:3280-3283.
23. Sharara, A. I., D. J. Perkins, M. A. Misukonis, S. U. Chan, J. A. Dominitz, and J. B. Weinberg. 1997. Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression-possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo. J. Exp. Med. 184:1495-1502.
24. Spitsin, S. V., H. Koprowski, and F. H. Michaels. 1996. Characterization and functional analysis of the human inducible nitric oxide synthase gene promoter. Mol. Med. 2:226-235.
25. Stevenson, M. M., M. F. Tam, S. F. Wolf, and A. Sher. 1995. IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism. J. Immunol. 155:2545-2556.
26. Tiao, G., J. Rafferty, C. Ogle, J. Fischer, and P. Hasselgren. 1994. Detrimental effect of nitric oxide synthase inhibition during endotoxemia may be caused by high levels of tumor necrosis factor and interleukin-6. Surgery 116:332-338.
27. Vodovotz, Y., C. Bogdan, J. Paik, Q. W. Xie, and C. Nathan. 1993. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J. Exp. Med. 178:505-613.
28. Weinberg, J. B. 1998. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol. Med. 4:557-591.
29. G-monomethyl-L-ar-ginine. J. Exp. Med. 179:651-660.
30. Weinberg, J. B., J. J. Muscato, and J. E. Niedel. 1981. Monocyte chemotactic peptide receptor. Functional characteristics and ligand-induced regulation. J. Clin. Investig. 68:621-630.
31. Wilding, E., S. Winkler, P. G. Kremsner, C. Brandts, L. Jenne, and W. H. Wemsdorfer. 1995. Malaria epidemiology in the province of Moyen Ogooue, Gabon. Trop. Med. Parasitol. 46:77-82.
32. World Health Organization. 1995. WHO fact sheet, vol. 94, p. 1-3. World Health Organization, Geneva, Switzerland.
33. World Health Organization. 1990. Severe and complicated malaria. Trans. R. Soc. Trop. Med. Hyg. 84(Suppl. 2):1-65.